nivolumab, and pembrolizumab). The 2 terminated studies (both for idelalisib) were stopped owing to significant safety concerns. One product (ponatinib) was temporarily pulled from the market, with the FDA requiring further studies, and a risk evaluation and mitigation strategy; however, the PMR clinical study eventually resumed and was completed. One ongoing trial (for olaparib) was released as a PMR by the FDA. None of the pending or ongoing studies are behind their original schedules as posted in the FDA's PMR database.
Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy
In 2017, the US Food and Drug Administration approved the drugs tisagenlecleucel (Kymriah; Novartis) and axicabtagene ciloleucel (Yescarta; Kite Pharma) as the first chimeric antigen receptor T-cell (CAR-T) immunotherapies. Treatment with tisagenlecleucel has been priced at $475 000 and axicabtagene ciloleucel at $373 000; however, these prices are for the drug products alone and do not account for the costs associated with leukapheresis, lymphodepletion therapy, and the adverse effects of CAR-T immunotherapy. These costs are not negligible as 43 patients (44%) who received tisagenlecleucel in clinical trials required stays in the intensive care unit for cytokine release syndrome (CRS). 1 In this study, we estimated the total costs of CAR-T immunotherapy, including nondrug costs, using publicly available data.
Methods | The institutional review board at the University of Pittsburgh deemed this study exempt. We divided the potential outcomes of patients selected for CAR-T immunotherapy into 11 scenarios, accounting for the receipt of treatment, development of CRS, and response to CAR-T immunotherapy ( Figure) . We calculated the probabilities of each scenario using input probabilities from the were calculated as 26% of facility costs. 5 All estimates were inflated to 2017 US dollars using the Consumer Price Index for Medical Care.
To estimate the mean expected cost per patient treated, we added up the expected costs of the drug product in each scenario and its expected probability and then divided the sum by the probability of being treated. Because Novartis, the manufacturer of tisagenlecleucel, offered to waive the costs of the drug for patients who do not demonstrate a response to treatment after 1 month, we estimated the costs of tisagenlecleucel with and without refunds for individuals with no treatment response.
Results | As the Table shows, the total costs of treatment with tisagenlecleucel per patient treated range from $478 777 for those without CRS to $531 823 for those with severe CRS (CRS grade ≥3). The mean expected cost is $510 963, which decreases to $432 131 under the outcomes-based pricing arrangement. The mean expected cost of axicabtagene ciloleucel per Letters patient treated is $402 647. With approximately 600 US patients eligible for tisagenlecleucel every year, the $432 131 estimate would translate into annual expenditures of $259 million. With 7500 US patients annually eligible for axicabtagene ciloleucel, the total expenditures would be more than $3 billion.
Discussion | To our knowledge, this study provides the first estimates of the total costs of CAR-T immunotherapy in the United States; these estimates are consistent with those previously calculated for the United Kingdom. 6 Although our study did not examine the benefits associated with CAR-T immunotherapy and hence does not provide estimates of costeffectiveness, it nevertheless has important implications. One could argue that the nondrug costs associated with CAR-T immunotherapy are negligible when compared with drug costs, as the former represent 7% of total costs. However, in absolute terms, these nondrug costs are $30 000 to $36 000 for the average patient and as high as $56 000 for those with severe CRS; these costs are equivalent to the costs of many of today's most expensive medications. Moreover, under the proposed outcomes-based pricing arrangement, nondrug costs are not refunded for patients who do not demonstrate a response to treatment. Payers and the public must understand that only the costs borne by the manufacturer, but not the total costs of CAR-T immunotherapy, will be reimbursed for those who display no treatment response. As the number of patients eligible for CAR-T immunotherapy and other expensive therapies increase, accurately measuring and accounting for the associated nondrug costs will be important when assessing the treatment's true costs and value and when negotiating pricing arrangements.
